Leap Therapeutics Inc.
(LPTX)
undefined
undefined%
At close: undefined
3.01
1.51%
After-hours Dec 13, 2024, 04:01 PM EST
Company Description
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer.
Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers.
Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand.
The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015.
Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Leap Therapeutics Inc.
| Country | United States |
| IPO Date | Jan 25, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 54 |
| CEO | Douglas E. Onsi J.D. |
Contact Details
Address: 47 Thorndike Street Cambridge, Massachusetts United States | |
| Website | https://www.leaptx.com |
Stock Details
| Ticker Symbol | LPTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001509745 |
| CUSIP Number | 52187K101 |
| ISIN Number | US52187K2006 |
| Employer ID | 27-4412575 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Douglas E. Onsi J.D. | Chief Financial Officer, General Counsel, Treasurer & Secretary, President, Chief Executive Officer & Director |
| Augustine J. Lawlor | Chief Operating Officer |
| Christine M. Granfield | Vice President and Head of Regulatory Affairs & Quality |
| Dr. Cynthia A. Sirard M.D. | Chief Medical Officer |
| Dr. Jason S. Baum Ph.D. | Chief Scientific Officer |
| Mark O'Mahony | Chief Manufacturing Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 15, 2024 | 4 | Filing |
| Nov 15, 2024 | 4 | Filing |
| Nov 15, 2024 | 4 | Filing |
| Nov 15, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 06, 2024 | S-8 | Filing |
| Oct 31, 2024 | SC 13D/A | [Amend] Filing |
| Oct 31, 2024 | SCHEDULE 13D/A | [Amend] Filing |